Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak Signed a Memorandum of Understanding with the Red Cross Concerning the Prosthetics and Orthotics

 
The Minister of Public Health Dr. Jamil Jabak signed a memorandum of understanding and collaboration with the International Committee of the Red Cross (ICRC) represented by Pablo Percelsi, the ICRC’s deputy head of delegation in Lebanon. The memorandum aims at improving the prosthetics services to the persons with disabilities.

In a statement, Minister Jabak expressed appreciation for this further collaboration with the Red Cross, since it will ensure the exchange of expertise in favor of the patients in need of prosthetics. He also acknowledged the humane efforts of the Red Cross in Lebanon, stressing that the Ministry is looking forward to further joint collaboration.

Percelsi noted that the International Committee is glad to sign the memorandum of understanding, especially that the prosthetics are considered as a main factor to restore hope and dignity of the people who lost a part of their body. He added that the new program reflects the continuing collaboration with the ministry and thanked Minister Jabak for his support in this field.

The Memorandum of understanding stipulates the support to Lebanon in the development of standards for prosthetics and orthotics through a benchmark study on the international standards that facilitate the access to the mobility equipment. It aims at ensuring the prosthetic and orthotic services in Lebanon are in conformity with the 2017 WHO standards for prosthetics and orthotics. The project is expected to lead to a benchmark statement for the prosthetic and orthotic services in Lebanon, which would result in a regional report on the development of the sector.
    ...
    126
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AA33 ENTYVIO BioTech Vedolizumab - 108mg 108mg Injectable solution 88,955,869 L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
B05CX01 DEXTROSE 20% INJECTION USP G Glucose - 20% 20% Injectable solution 316,025 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 108mg 108mg Injectable solution 88,955,869 L.L
B05CX01 DEXTROSE 20% INJECTION USP G Glucose - 20% 20% Injectable solution 183,869 L.L
C03CA01 FRURETIC G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 2,600,655 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 148,244 L.L
C03CA01 FUROLIX G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,612,611 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 148,244 L.L
C03CA01 FUROSEMIDE RENAUDIN G Furosemide (sodium) - 20mg/2ml 20mg/2ml Injectable solution 451,531 L.L
N05AF05 CLOPIXOL DEPOT B Zuclopenthixol decanoate - 200mg/ml 200mg/ml Injectable solution 512,004 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 159,736 L.L
C03CA01 FUROSEMIDE SALF G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 216,359 L.L
N05AF05 CLOPIXOL ACUPHASE B Zuclopenthixol acetate - 100mg/2ml 100mg/2ml Injectable solution 857,372 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 179,272 L.L
C03CA01 URO-CARE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,630,081 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 191,913 L.L
C03CA01 FUROSEMIDE RENAUDIN G Furosemide - 250mg/25ml 250mg/25ml Injectable solution 1,791,342 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 191,913 L.L
C03CA01 FUROSEMIDE S.A.L.F. G Furosemide - 250mg/25ml 250mg/25ml Injectable solution 919,188 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 208,002 L.L
L04AA52 KESIMPTA BioTech Ofatumumab - 20mg/0.4ml 20mg/0.4ml Injectable solution 96,542,598 L.L
N05AX12 ABILIFY MAINTENA B Aripiprazole - 400mg 400mg Injectable powder for suspension, prolonged release+solvent 29,491,998 L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 20mg 20mg Injectable powder for suspension+diluent 36,504,302 L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 30mg 30mg Injectable powder for suspension+diluent 54,757,132 L.L
L02AE04 DECAPEPTYL LP B Triptorelin (pamoate) - 3mg 3mg Injectable powder for suspension+diluent 11,778,312 L.L
L02AE04 DECAPEPTYL LP B Triptorelin (pamoate) - 11.25mg 11.25mg Injectable powder for suspension+diluent 31,761,098 L.L
L02AE04 GONAPEPTYL CR B Triptorelin - 3.75mg 3.75mg Injectable powder for suspension+diluent 12,095,730 L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 20mg 20mg Injectable powder for suspension+diluent L.L
H01CB02 SANDOSTATIN LAR B Octreotide (acetate) - 30mg 30mg Injectable powder for suspension+diluent L.L
    ...
    126
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025